Willow Biosciences Closes $28.8 Million Bought Deal Financing

Willow Biosciences (TSX: WLLW) on Friday closed their previously announced bought deal financing. The company raised a total of $28.8 million in gross proceeds, which includes the full exercise of the over-allotment option issued in connection with the offering.

The financing saw the company sell common shares of the company at a price of $1.65 per each, with no warrant being included in the offering. A total of 17.4 million shares were issued in connection with the financing. Notably, the company indicated that the offering was “comprised primarily of existing cornerstone shareholders and new institutional buyside funds.”

Proceeds from the financing are to be used to expand market access for the firms cannabinoids portfolio, to add to its current manufacturing capacity, and for working capital and general corporate purposes.

“The strong cash position of Willow allows us as an organization to have significantly more negotiating leverage with potential business development opportunities. With commercialization of our first cannabinoid expected to occur in Q1 2021, marking the final step in our transition to becoming a revenue generating company, we are in a very strong position to generate value for Willow stakeholders.”

Trevor Peters, CEO of Willow Biosciences

Willow Biosciences last traded at $1.72 on the TSX.


FULL DISCLOSURE: Willow Biosciences Inc is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Willow Biosciences Inc on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Tudor Gold x American Creek: Consolidating A Massive Gold Project

Aura Minerals: The Era Dorada Underground PEA

Gold Is Now Smart Money’s End Game | Doug Casey

Recommended

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Emerita Resources Formally Appeals Administrative Ruling On Aznalcóllar Related To 2017 Complaint 

Related News

Willow Biosciences: Jazz Pharma – GW Pharma Merger Has Positive Read-Through For Company

Last week’s announcement that Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has agreed to buy GW Pharmaceuticals...

Sunday, February 14, 2021, 09:00:00 AM

Willow Biosciences: First Commercial Fermentation Of CBG Completed – The Daily Dive

Today on the Daily Dive, we sit down with that of Trevor Peters, CEO of...

Wednesday, March 31, 2021, 01:30:00 PM

Willow Biosciences Increases Bought Deal Financing To $25.0 Million

Late last night, Willow Biosciences (TSX: WLLW) announced the upsizing of its bought deal financing...

Friday, February 12, 2021, 07:25:43 AM

Willow Biosciences Looks To Launch Biosynthesized THC In Canadian Market

Willow Biosciences (TSX: WLLW) this morning had a major announcement, with the company announcing that...

Tuesday, January 19, 2021, 09:04:44 AM

Willow Biosciences Completes Study On Use Of CBG On Skin

Willow Biosciences (TSX: WLLW) appears to be backing up its proprietary IP with clinical trials....

Tuesday, April 20, 2021, 07:07:08 AM